In its broadest mission, the Immunoassay Core provides technical support and services for the application and innovation of immunoassays. These activities serve as a critical link between basic and clinical investigators. Members of BADERC can access state-of-the-art commercial immunoassays for measuring a wide range of analytes. Many of these are fully automated, high speed systems that can support very large testing volumes and multi-site studies. Importantly, the Immunoassay Core is experienced in adapting these systems to measurements using animal serum or plasma (rats and mice.) The Core also provides access to radioimmunoassay that has been established for many years in Dr Habener's laboratory for metabolic studies in animals and humans. Access to well validated and standardized assays provides interpretive power based upon large normative and pathophysiologic databases thus serving as a crucial backdrop for clinical investigations. The effort to translate basic research into clinical advances benefits by our ability to expedite the transfer of newly identified biomarkers into novel assays that meet the need for the high volume, precise, and sensitive clinical measurements needed to objectively assess the value of new biomarkers. As investigators increasingly focus upon the genetic basis of human disease, an effective mechanism is needed to provide the requisite analytic methods to characterize phenotypic correlates and to assess the incidence of specific genetic-based defects in clinical (e.g., human) and animal models. The Immunoassay Core provides monoclonal facilities and expertise in the generation of antibodies for immunoassay and reagents.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK057521-08
Application #
7550755
Study Section
Special Emphasis Panel (ZDK1)
Project Start
2007-04-01
Project End
2010-03-31
Budget Start
2007-04-01
Budget End
2008-03-31
Support Year
8
Fiscal Year
2007
Total Cost
$99,927
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Vujic, Ana; Lerchenmüller, Carolin; Wu, Ting-Di et al. (2018) Exercise induces new cardiomyocyte generation in the adult mammalian heart. Nat Commun 9:1659
Fulzele, Keertik; Dedic, Christopher; Lai, Forest et al. (2018) Loss of Gs? in osteocytes leads to osteopenia due to sclerostin induced suppression of osteoblast activity. Bone 117:138-148
Battistone, Maria A; Nair, Anil V; Barton, Claire R et al. (2018) Extracellular Adenosine Stimulates Vacuolar ATPase-Dependent Proton Secretion in Medullary Intercalated Cells. J Am Soc Nephrol 29:545-556
Cheung, Pui W; Terlouw, Abby; Janssen, Sam Antoon et al. (2018) Inhibition of non-receptor tyrosine kinase Src induces phosphoserine 256-independent aquaporin-2 membrane accumulation. J Physiol :
Karim, Lamya; Moulton, Julia; Van Vliet, Miranda et al. (2018) Bone microarchitecture, biomechanical properties, and advanced glycation end-products in the proximal femur of adults with type 2 diabetes. Bone 114:32-39
Kolar, Matthew J; Nelson, Andrew T; Chang, Tina et al. (2018) Faster Protocol for Endogenous Fatty Acid Esters of Hydroxy Fatty Acid (FAHFA) Measurements. Anal Chem 90:5358-5365
Todd, William D; Fenselau, Henning; Wang, Joshua L et al. (2018) A hypothalamic circuit for the circadian control of aggression. Nat Neurosci 21:717-724
Cox, Kimberly H; Oliveira, Luciana M B; Plummer, Lacey et al. (2018) Modeling mutant/wild-type interactions to ascertain pathogenicity of PROKR2 missense variants in patients with isolated GnRH deficiency. Hum Mol Genet 27:338-350
Aguayo-Mazzucato, Cristina; Bonner-Weir, Susan (2018) Pancreatic ? Cell Regeneration as a Possible Therapy for Diabetes. Cell Metab 27:57-67
McKeown, Nicola M; Dashti, Hassan S; Ma, Jiantao et al. (2018) Sugar-sweetened beverage intake associations with fasting glucose and insulin concentrations are not modified by selected genetic variants in a ChREBP-FGF21 pathway: a meta-analysis. Diabetologia 61:317-330

Showing the most recent 10 out of 389 publications